Skip to content
Media Hub UK

Individuals Stopping Weight-Loss Jabs Put On Pounds Four Times Faster Compared to People Using Diet and Exercise

Image of medical injection and weighing machine
Obesity treatment involves ongoing approaches.

A recent study suggests that individuals who come off popular weight-loss injections like Mounjaro or Wegovy tend to recover lost weight much more quickly than those who end conventional lifestyle programs.

Findings released in a leading medical journal shows that while obese people often shed a large proportion of their body weight while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.

"People buying these treatments should be aware of the danger of rapid rebound weight gain when the medication concludes," stated researcher Dr. Susan Jebb.

This pace of regain implies a return to original weight in about a year and a half.

Analyzing Therapies

The study, which examined dozens of trials involving over 9,000 of patients, compared the effects of the injectable medications with other pills.

The team emphasize that individuals who lose weight through dieting typically experience a slower creep back—approximately 0.1 kg a month—post-intervention.

The Reason for the Rapid Rebound

Nutrition scientists propose the way of the jabs is key to understanding the accelerated regain.

The injections copy a natural hormone called GLP-1, which moderates appetite.

"Sustained high doses of GLP-1 concentrations several times higher than normal could lead to the system to produce less of its own natural hormone, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition researcher.

"Stopping of this medication results in hunger is unsuppressed, making binge eating a significant risk."

An Ongoing Issue?

Medical guidelines advise the jabs for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.

A number of clinicians argue that, due to the significant potential of weight regain, the treatment is often long-term.

This perspective is echoed by drug manufacturers, who say that the findings "highlight the persistent nature of obesity," similar to managing diseases like high blood pressure.

User Testimonies

Users who have discontinued the medication describe a intense resurgence of appetite.

"I experienced a switch activating and I was suddenly extremely hungry," recalled one woman.

This difficulty is worsened if patients have not established lasting lifestyle or habit changes during therapy.

Significant Use

Recent estimates show that millions of people in the UK have tried these injections in the past year, with desire remaining high.

  • Adoption is greater among women than men.
  • The 40s and 50s demographic shows the highest usage rates.
  • A large proportion access the medications through private healthcare rather than public health services.

Ultimately, researchers caution that while GLP-1 drugs are effective agents for weight loss, they are not a standalone solution and long-term success relies on combined lifestyle changes.

The writer

Mr. Donald Mcfarland

Elara is a multimedia journalist with over a decade of experience in digital media, specializing in tech innovation and cultural reporting.

Media Hub UK

Type to search articles.